ArticleThe oncologist2020

Contextualizing the Use of Moxetumomab Pasudotox in the Treatment of Relapsed or Refractory Hairy Cell Leukemia.

Robert J Kreitman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.